Recombinant dimeric envelope vaccine against flaviviral infection
CA 2298538 A1 · Owner: Hawaii Biotech, Inc. · Inventors: Peters, Iain D.; Harada, Kent E.; Ivy, John M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses and claims vaccines containing as an active , ingredient, a secreted recombinantly produced dimeric form of a truncated flaviviral envelope protein. The vaccines are capable of eliciting the production of neutralizing antibodies against flaviviruses. One embodiment of the present invention is directed to a vaccine for protection of a subject against infection by dengus virus. The dimeric truncated E is secreted as a recombinantly produced protein from eukaryotic cells. The vaccine may further contain portions of additional dengue virus serotype dimeric E proteins similarly produced. Another embodiment of the present invention is directed to methods to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 27, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 27, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 27, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.